Metronidazole hydrochloride (SC 326421) 是一种具有口服活性的硝基咪唑类抗生素，能用于研究厌氧微生物的感染。Metronidazole hydrochloride 能够穿过血脑屏障，长期使用会导致炎症和骨骼肌收缩。
Cas No.:69198-10-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Metronidazole hydrochloride (SC 326421) is an orally active nitroimidazole antibiotic, can be used to research anaerobic infections. Metronidazole hydrochloride can cross blood brain barrier and results inflammation and skeletal muscle contraction under long-term application[1][2][3][4].
In Vitro, Metronidazole hydrochloride acts on anaerobic microorganism following: passage through the cell membrane; (b) reductive action; (c) interaction with intracellular targets; (d) release of inactive end products, exerts function with toxic nitro and nitroso derivatives[1].
Metronidazole hydrochloride displays inhibitory activity towards anaerobic protozoa Trichomonas vaginalis, Entamoeba histolytica, Giardia lamblia, and Balantidium coli[1].
Metronidazole hydrochloride (4-8 μg/mL) inhibits anaerobic bacteria and shows good bactericidal activity[1].
Metronidazole hydrochloride (0.1 μg/mL-0.01 mg/mL; 12-96 h) induces granular formation and triggers apoptosis in Blastocystis sp[2].
In Vivo, Metronidazole hydrochloride (135 mg/kg/d; p.o.; 28 d) can cross the blood brain barrier, and exhibits neurotoxicity under long term administration in rats[3].
Metronidazole hydrochloride (1 g/L; p.o.; 4 weeks) results skeletal muscle atrophy and changes the expression of genes involved in the muscle peripheral circadian rhythm machinery and metabolic regulation[4].
References:
[1]. Scully BE. Metronidazole. Med Clin North Am. 1988 May;72(3):613-21.
[2]. Dhurga DB, et al. Granular Formation during Apoptosis in Blastocystis sp. Exposed to Metronidazole (MTZ). PLoS One. 2016 Jul 29;11(7):e0155390.
[3]. Chaturvedi S, et al. Mechanistic exploration of quercetin against metronidazole induced neurotoxicity in rats: Possible role of nitric oxide isoforms and inflammatory cytokines. Neurotoxicology. 2020 Jul;79:1-10.
[4]. Manickam R, et al. Metronidazole Causes Skeletal Muscle Atrophy and Modulates Muscle Chronometabolism. Int J Mol Sci. 2018 Aug 16;19(8):2418.
Metronidazole hydrochloride (SC 326421) 是一种具有口服活性的硝基咪唑类抗生素，能用于研究厌氧微生物的感染。Metronidazole hydrochloride 能够穿过血脑屏障，长期使用会导致炎症和骨骼肌收缩。
| Cas No. | 69198-10-3 | SDF | |
| 别名 | 盐酸甲硝唑; SC 326421 | ||
| Canonical SMILES | OCCN1C([N+]([O-])=O)=CN=C1C.[H]Cl | ||
| 分子式 | C6H10ClN3O3 | 分子量 | 207.61 |
| 溶解度 | DMSO : 100 mg/mL (481.67 mM; Need ultrasonic) | 储存条件 | -20°C |
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.8167 mL | 24.0836 mL | 48.1672 mL |
| 5 mM | 963.3 μL | 4.8167 mL | 9.6334 mL |
| 10 mM | 481.7 μL | 2.4084 mL | 4.8167 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: An oil
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet